ERBB2 and gallbladder cancer: Preclinical studies have revealed that genomic ERBB2/ERBB3 mutations promote PD-L1–mediated immune escape in gallbladder cancer through inhibiting the ability of tumor-reactive T cells and attenuating the release of Interferon (IFN-γ) and Interleukin-2 (IL-2) (11).